---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-049281"
form_type: "8-K"
ticker: "ARWR"
cik: "0000879407"
company_name: "ARROWHEAD PHARMACEUTICALS, INC."
filed_at: "2024-11-26T23:59:59+00:00"
generated_at: "2026-05-29T18:26:14.150570+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Arrowhead reports FY2024 net loss $599.5M; inks Sarepta deal, files plozasiran NDA

## Summary
- Net loss of $599.5M (-$5.00 diluted EPS) vs $205.3M loss (-$1.92) in FY2023.
- Revenue fell to $3.55M from $240.7M, primarily due to lower collaboration revenue.
- Signed licensing deal with Sarepta: $825M upfront ($500M cash, $325M equity), plus $250M over 5 years.
- Closed $500M senior secured credit facility with Sixth Street; $400M funded at close.
- Submitted NDA for plozasiran (FCS) and received Breakthrough Therapy designation from FDA.

## SEC filing metadata
- accession: 0001628280-24-049281
- form_type: 8-K
- ticker: ARWR
- cik: 0000879407
- company_name: ARROWHEAD PHARMACEUTICALS, INC.
- filed_at: 2024-11-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879407/000162828024049281/0001628280-24-049281-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879407/000162828024049281/arwr-20241126.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-049281
- JSON: https://secwatch.observer/filing/0001628280-24-049281.json
- Plain text: https://secwatch.observer/filing/0001628280-24-049281.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.